BioCryst Pharmaceuticals | BCRX - Operating Profit


BioCryst Pharmaceuticals reported $260.38M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Chugai Pharma JPY 158.77B 10.24B Mar/2026
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
DBV Technologies USD -47.9M 2.85M Mar/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Gilead Sciences USD 2.68B 284M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Glaxosmithkline GBP 2.29B 3.08M Mar/2026
Incyte USD 324.17M 59.7M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Novavax USD 20.94M 100.32M Dec/2025
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026